Kiniksa Pharmaceuticals International PLC
(NAS:KNSA)
$
74.34
-3.84 (-4.91%)
Market Cap: 5.80 Bil
Enterprise Value: 5.28 Bil
PE Ratio: 76.64
PB Ratio: 8.86
GF Score: 46/100 Kiniksa Pharmaceuticals International PLC at JPMorgan Healthcare Conference Transcript
Jan 12, 2026 / 10:15PM GMT
Release Date Price:
$41.12
(-3.63%)
Anupam Rama
JPMorgan Chase & Co - Analyst
All right. Let's go ahead and get started. Welcome, everyone, to the 44th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan.
I'm joined by my squad, Priyanka Grover, Joyce Zhou, and Rati Pinge. The next presenting company is Kiniksa and presenting on behalf of the company, we have CEO, Sanj Patel. Sanj?
Sanjiv Patel
Kiniksa Pharmaceuticals International PLC - Chairman of the Board, Chief Executive Officer
Thank you, Anupam. It's always a pleasure, and thank you to JPMorgan for hosting us today. I was just thinking Anupam, we've been doing this for quite a long time together. I think it's almost 20 years, at least 18 years. And I still think we're pretty sprightly in chipper.
What do you think?
Anupam Rama;Sanjiv Patel
JPMorgan Chase & Co - Analyst;Kiniksa Pharmaceuticals International PLC - Chairman of the Board,
Yes, I think so. I think so.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot